Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT-SLE upadacitinib in moderately to severely active systemic lupus erythematosus
2023-503655-10-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 38
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Upadacitinib with Placebo (2 arms). Primary endpoints: BICLA response at Week 52, No primary endpoint (Study 3) and 1 more. Planned start Oct 2023; status: authorised.
02
Drugs
upadacitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2023-503655-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503655-10-00.